Analgesic efficacy of addition of Dexmedetomidine versus Nalbuphine to bupivacaine in bilateral intermediate cervical plexus block for thyroidectomy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR202510614699556

Enrollment

Registered

2025-10-30

Start date

2025-08-21

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Surgery

Interventions

group Dexmedetomidine

group Nalbuphine

Control group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: American Society of anesthesiologistd physical status grades 1,2,3 Age between 19 and 65 years Both sexes

Exclusion criteria

Exclusion criteria: Patient refusal, haematological diseases, renal, hepatic or cardiac diseases , pregnancy, Neuromuscular , neurological or psychological diseases, known hypersensitivity, cancer patients with ongoing opioid therapy

Design outcomes

Primary

Measure	Time frame
Primary outcome :is time to first analgesic request	—

Secondary

Measure	Time frame
Secondary outcomes are VAS at 0,2,4,8,12and 24 hours / ERAS/Richmond agitation sedation score	—

Countries

Egypt

Contacts

Public ContactGhada fouad Mohamed weefky

assistant professor of anesthesia and surgical intensive care

ghadafouad@mans.edu.eg01008081333

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026